Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2008 /
Endoxifen levels in Breast Cancer patients and testing for CYP2D6

10th - 14th Dec 2008

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.01.09
Views: 16423

Dr John Hawse, Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine

Patients receiving tamoxifen therapy who can produce high levels of endoxifen have better survival than those producing low levels - why is this? Test needed for patients with CYP2D6 gene prior to administering tamoxifen

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation